| 2.39 0.04 (1.7%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.52  |
1-year : | 4.02 |
| Resists | First : | 3.02 |
Second : | 3.45 |
| Pivot price | 2.68 |
|||
| Supports | First : | 2.32 |
Second : | 1.93 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.76 |
| MA(100) : | 2.77 |
MA(250) : | 1.93 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.2 |
D(3) : | 15.7 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 4.38 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADAG ] has closed above bottom band by 8.5%. Bollinger Bands are 30.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.58 - 2.59 | 2.59 - 2.61 |
| Low: | 2.3 - 2.32 | 2.32 - 2.33 |
| Close: | 2.37 - 2.39 | 2.39 - 2.41 |
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Thu, 11 Apr 2024
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 38.6% in March - MarketBeat
Sun, 31 Mar 2024
Adagene Full Year 2023 Earnings: US$1.83 loss per share (vs US$1.85 loss in FY 2022) - Simply Wall St
Fri, 29 Mar 2024
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Thu, 07 Mar 2024
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewswire
Tue, 27 Feb 2024
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - GlobeNewswire
Fri, 09 Feb 2024
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 1.299e+007 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.274e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -104.7 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 288.8 % |
| Return on Equity (ttm) | -11.1 % |
| Qtrly Rev. Growth | 1.811e+007 % |
| Gross Profit (p.s.) | -188.45 |
| Sales Per Share | -54.81 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.67 |
| Dividend | 0 |
| Forward Dividend | 13690 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|